SLE患者外周血T、B淋巴细胞TLR9蛋白表达及与临床指标的关系

目的 探讨SLE患者外周血B、T淋巴细胞中Toll样受体9(TLR9)蛋白的表达水平及其与相关临床指标间的关系.方法 B、T淋巴细胞及TLR9蛋白各自用荧光抗体标记,用流式细胞仪测定35例新诊断但尚未经治疗的SLE患者及16例正常人对照外周血B、T淋巴细胞中TLR9蛋白的表达水平,分析TLR9蛋白表达水平与相关临床指标间的相关性.结果 SLE患者T、B淋巴细胞中表达TLR9蛋白的细胞百分比分别为(53.94±17.95)%、(49.33±23.30)%,对照组分别为(29.40±10.54)%、(29.18±14.78)%,两组相比差异有统计学意义(t值分别为6.11,3.73,P值均＜0.01).表达TLR9蛋白的B细胞百分比与SLEDAI成负相关(r=-0.39,P=0.02),与IgA表达量成正相关(r=0.74,P＜0.01).结论 初发未治型SLE患者TLR9蛋白表达水平较对照组升高,表达TLR9蛋白的B细胞百分比与SLEDAI成负相关,与IgA表达量成正相关.

Expressions of Ton-like receptor 9 protein in peripheral B and T lymphocytes from patients with systemic lupus erythematosus and their relationship with clinical parameters

Objective To study the expressions of Toll-like receptor 9 protein (TLR9) in peripheral B and T lymphocytes in newly diagnosed, untreated patients with systemic lupus erythematosus (SLE) and their relationship with clinical parameters. Methods Blood samples were obtained from 35 newly diag-nosed, untreated patients with SLE and 16 healthy human controls. B, T lymphocytes and TLR9 protein were labeled with fluorescent antibodies, and the expressions of TLR9 protein were detected by flow cytometry in peripheral B and T lymphocytes. The relationship between TLR9 expression and clinical parameters was assessed. Results The proportions of B and T lymphocytes expressing TLR9 in newly diagnosed, untreated patients were (53.94±17.95)% and (49.33 ± 23.30)%, respectively, compared to (29.40 ± 10.54)% and (29.18 ± 14.78)%, respectively, in healthy controls (t = 6.11,3.73, respectively, both P < 0.01). Additionally,the proportion of B lymphocytes expressing TLR9 correlated negatively with SLE disease activity index (SLEDAI)(r = -0.39, P < 0.05), but positively with the level of serum IgA antibody (r = 0.74, P < 0.01).Condnsions The expression of TLR9 is elevated in peripheral T and B lymphocytes from patients with newly diagnosed, untreated SLE, and the proportion of TLR9-expressing B lymphocytes negatively correlates with SLEDAI, but positively correlates with the serum level of IgA antibody.